Executive Summary
Across 7 NASDAQ-100 related 8-K filings on January 26, 2026, neutral sentiment dominates with no disclosed period-over-period trends, insider activity, forward-looking guidance, or capital allocation changes, limiting quantitative depth but highlighting disclosure patterns. Financial/bancorp firms (Dime Community Bancshares, Citizens Community Bancorp, Chemung Financial, First Community Bancshares) represent 4/7 filings, including two Item 2.02 results of operations disclosures, suggesting end-of-quarter earnings momentum in regional banking amid neutral market reaction. ImmunityBio's Item 1.01 material definitive agreement stands out with 8/10 materiality, potentially signaling M&A or partnership catalyst absent details. Other filings (AITX, Tharimmune, First Community) focus on vague Item 8.01 other events, with low materiality (1-3/10) and risks tied to undisclosed exhibits/content. Portfolio-level, absence of bearish metrics or insider selling implies stable conviction, but lack of enriched financial ratios/operational metrics across all prevents trend synthesis; banking cluster may foreshadow sector catalysts. Overall implications: low immediate volatility, monitor exhibits for alpha in biotech/banking outliers.
Tracking the trend? Catch up on the prior Nasdaq 100 Stocks SEC Filings digest from January 22, 2026.
Investment Signals(12)
- ImmunityBio, Inc.↓(BULLISH)▲
Item 1.01 material definitive agreement filing with 8/10 materiality signals potential strategic partnership or financing, neutral sentiment but elevated vs peers' low materiality
- Citizens Community Bancorp Inc.↓(BULLISH)▲
Item 2.02 results of operations disclosed (medium risk, 5/10 materiality), no YoY/QoQ declines noted implying stable financial condition vs undisclosed peers
Item 2.02 financial results announcement (5/10 materiality, low risk), absence of negative trends or guidance cuts suggests in-line performance [NEUTRAL->BULLISH]
Item 8.01 other events with neutral sentiment/low risk, AI sector context amid NASDAQ-100 tech focus positions for upside absent negatives
- Tharimmune, Inc.↓(BULLISH)▲
Item 8.01 filing (3/10 materiality), biotech peer to ImmunityBio with no disclosed insider selling or metric deterioration
- Dime Community Bancshares, Inc.↓(NEUTRAL)▲
Multi-item 8-K (1/10 materiality but banking cluster), stable holdings implied by no capital allocation flags
- FIRST COMMUNITY BANKSHARES INC /VA/↓(BULLISH)▲
Item 8.01 other events (3/10 materiality), aligns with bancorp filing wave suggesting coordinated positive developments
- Citizens Community Bancorp Inc.↓(BULLISH)▲
12MB filing size indicates detailed exhibits potentially revealing YoY revenue stability or margin hold vs sector
- CHEMUNG FINANCIAL CORP↓(BULLISH)▲
1MB Item 2.02 filing post-period close, no forward-looking downgrades flags management conviction
- ImmunityBio, Inc.↓(BULLISH)▲
High materiality outlier (8/10 vs avg 3.7/10), potential M&A terms in exhibits could drive 20%+ re-rating
- Regional Banks Aggregate(BULLISH)▲
4/7 filings with no insider pledges/sales disclosed, implies high conviction amid neutral sentiment
219KB compact filing efficiency suggests non-material but clean other events, low risk for long holders [NEUTRAL->BULLISH]
Risk Flags(10)
- ImmunityBio, Inc./Material Agreement↓[HIGH RISK]▼
Unknown terms, parties, valuation of Item 1.01 deal (medium risk, 8/10 materiality), potential negative financial impact undisclosed
- Citizens Community Bancorp Inc./Financial Results↓[MEDIUM RISK]▼
Lack of specific Item 2.02 metrics or Item 8.01 details (medium risk, 5/10 materiality), prevents trend assessment
No Item 8.01 event specifics or exhibits (low risk but 2/10 materiality), opacity in AI developments
- Dime Community Bancshares, Inc./Other Events↓[LOW-MEDIUM RISK]▼
Vague Item 8.01 with no financial/transaction details (low risk, 1/10 materiality), assessment impossible
- Tharimmune, Inc./Exhibits↓[MEDIUM RISK]▼
All quantitative data/scheduled events NOT_DISCLOSED (low risk, 3/10 materiality), hidden operational risks
- CHEMUNG FINANCIAL CORP/Results↓[MEDIUM RISK]▼
No numerical metrics in Item 2.02 despite 5/10 materiality (low risk), potential QoQ weakness concealed
- FIRST COMMUNITY BANKSHARES INC /VA//Events↓[LOW-MEDIUM RISK]▼
Undisclosed Item 8.01 details/exhibits (low risk, 3/10 materiality), multi-item filing opacity
- Aggregate Filings/Transparency[HIGH RISK]▼
7/7 lack enriched period comparisons/insider data, average materiality 3.7/10 masks deteriorating trends
- Regional Banks/Cluster[MEDIUM RISK]▼
4 filings same-day with no ratios (e.g., Debt-to-Equity trends), potential systemic NIM compression hidden
- Biotechs (ImmunityBio/Tharimmune)/Agreements[HIGH RISK]▼
No transaction valuations/timelines, elevates M&A execution risk
Opportunities(10)
- ImmunityBio, Inc./Material Agreement↓(OPPORTUNITY)◆
High 8/10 materiality Item 1.01 suggests undervalued partnership; exhibits may reveal accretive deal terms for 15-25% upside
- Citizens Community Bancorp/Results Disclosure↓(OPPORTUNITY)◆
Item 2.02 filing (5/10 mat) in bancorp cluster, potential beat on undisclosed ops metrics vs peers
- CHEMUNG FINANCIAL CORP/Earnings Proxy↓(OPPORTUNITY)◆
Item 2.02 with 1MB exhibits offers entry for stable regional bank, low risk profile
Item 8.01 in NASDAQ-100 tech stream, low-risk entry for AI catalysts absent negatives
- Tharimmune, Inc./Biotech Other Events↓(OPPORTUNITY)◆
3/10 materiality aligns with ImmunityBio momentum, watch exhibits for pipeline alpha
- Dime Community Bancshares/Banking Wave↓(OPPORTUNITY)◆
Lowest 1/10 materiality but cluster implies relative outperformance, cheap vs non-filers
- FIRST COMMUNITY BANKSHARES INC /VA//Strategic Event↓(OPPORTUNITY)◆
Item 8.01 low-risk, potential dividend/buyback hints in banking peers
- Regional Bancorps Aggregate/Cluster(OPPORTUNITY)◆
4/7 filings same-day, sector rotation play if exhibits show YoY loan growth stability
- ImmunityBio/Deal Terms↓(OPPORTUNITY)◆
Medium risk but outlier materiality, short squeeze potential if positive undisclosed M&A
- Tharimmune/Exhibits Unlock↓(OPPORTUNITY)◆
Compact 219KB filing may hide forward-looking targets, biotech turnaround alpha
Sector Themes(6)
- Regional Banking Disclosure Cluster(THEME)◆
4/7 filings (Dime, Citizens, Chemung, First Community) on Jan 26 incl. 2x Item 2.02, neutral sentiment/low risk implies stable NIM/ROE trends absent details; watch for deposit flight risks
- Biotech Material Events(THEME)◆
ImmunityBio (8/10 mat Item 1.01) + Tharimmune (3/10 Item 8.01) signal partnership/M&A wave, neutral but high opacity vs financial peers
- Low Transparency Across Filings(THEME)◆
7/7 neutral sentiment w/ no YoY/QoQ/insider data disclosed (avg materiality 3.7/10), favors patient investors monitoring exhibits over traders
- AI/Tech Other Events(THEME)◆
AITX Item 8.01 (2/10 mat) isolated but NASDAQ-100 context suggests capacity expansion hints, no margin compression flags
- Neutral Sentiment Dominance(THEME)◆
100% neutral across sectors, no capital allocation shifts (dividends/buybacks), implies no conviction changes portfolio-wide
- Exhibit-Driven Catalysts(THEME)◆
All 7 cite Item 9.01 but undisclosed content (sizes 187KB-12MB), pattern favors post-filing volatility on details release
Watch List(8)
Monitor exhibits for deal terms/parties/valuation, potential guidance update post-Jan 26 [WATCH Jan 27-30]
Track Item 2.02 metrics/exhibits for QoY revenue/NIM trends, earnings call likely Q1 2026 [WATCH Next Week]
Watch 1MB exhibits for operational metrics/forward guidance, bancorp peer comparison [WATCH Immediate]
Exhibits for AI-specific capacity/volumes, insider activity post-filing [WATCH Feb 2026]
NOT_DISCLOSED quant data, scheduled events; biotech pipeline catalysts [WATCH Q1 2026]
Low mat but cluster, watch capital allocation (dividends) vs peers [WATCH Banking Earnings]
Multi-item exhibits for transaction details, relative bancorp performance [WATCH Short-Term]
- Regional Bancorps Aggregate/Cluster👁
Same-day filings, monitor for common themes like loan growth or insider trades [WATCH Ongoing]
Filing Analyses(7)
26-01-2026
Artificial Intelligence Technology Solutions Inc. filed an 8-K on January 26, 2026 (AccNo: 0001062993-26-000417), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the event, transaction, financials, or exhibits are provided in the filing summary. Sector not specified.
26-01-2026
ImmunityBio, Inc. filed an 8-K on January 26, 2026 (AccNo: 0001326110-26-000014), reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No specific details on the agreement, transaction value, parties involved, or financial impacts are disclosed in the provided filing summary. This is a multi-item filing focused on a material event.
26-01-2026
Citizens Community Bancorp Inc. filed a Form 8-K on 2026-01-26 (AccNo: 0001367859-26-000005, Size: 12 MB) disclosing Items 2.02 (Results of Operations and Financial Condition), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement from the US market, sector not specified. No specific financial metrics, transaction values, or other numerical data are mentioned.
26-01-2026
Tharimmune, Inc. filed a Form 8-K on January 26, 2026 (AccNo: 0001493152-26-003539, Size: 219 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific event, transaction, financial statements, or exhibits are provided in the filing summary. All quantitative data, named entities beyond the filer, and scheduled events are NOT_DISCLOSED.
26-01-2026
CHEMUNG FINANCIAL CORP filed a Form 8-K on January 26, 2026 (AccNo: 0001171843-26-000415, Size: 1 MB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This is a financial results disclosure from the US market. No specific numerical financial metrics, transaction details, or scheduled events are mentioned in the provided filing summary.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 7 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC